$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Which class of drugs does Anagrelide belong to and its clinical treatment positioning and scope of application?
2026-02-01 22:25:32
Check Details
How long does a course of apalutamide (Ansenko) usually take and its efficacy evaluation
2026-02-01 22:25:32
Check Details
What safety precautions and contraindications should be paid attention to when taking Elacetrant?
2026-02-01 22:25:32
Check Details
The top ten contraindications of F/TAF and the risks and precautions that must be avoided when taking it
2026-02-01 22:25:32
Check Details
The dosage and usage specifications of Febuxostat (Febuxostat) and the adjustment plan according to the patient's condition
2026-02-01 22:25:32
Check Details
Furmonertinib side effects usually begin to appear within a few days and analysis of symptoms
2026-02-01 22:25:32
Check Details
Safety precautions and contraindications you need to pay attention to while taking ensifentrine-Ohtuvayre
2026-02-01 22:25:32
Check Details
Why is it not recommended to take Roaccutane (Isotretinoin) at night? Choose the medication time scientifically
2026-02-01 22:25:32
Check Details
Is doxorubicin hydrochloride a chemotherapy drug? Introduction to drug categories and common combination regimens
2026-02-01 22:25:32
Check Details
Which groups of people are not suitable for taking everolimus (Afinitor)?
2026-02-01 22:25:32
Check Details
How long does it take for estramustine (Adelox) to take effect?
2026-02-01 22:25:32
Check Details
Interactions between Seripalase (BRINEURA) and other drugs and description of risks of combined use
2026-02-01 22:25:32
Check Details
1
2
...
2199
2200
2201
2202
2203
2204
2205
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
2
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
3
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
4
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
5
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
6
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
7
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
8
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
9
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
10
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
11
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
12
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide